EpiCept stops drug discovery and reduces staff
This article was originally published in Scrip
Executive Summary
EpiCept is discontinuing all drug discovery activities and is shedding 17 staff to concentrate on the registration of its anticancer Ceplene (histamine dihydrochloride) and other clinical programmes.